Apoptosis-mediated selective killing of malignant cells by cardiac steroids: Maintenance of cytotoxicity and loss of cardiac activity of chemically modified derivatives

International Immunopharmacology

Volumn 3, Issue 13-14, 2003, Pages 1791-1801

  Daniel, Dinara ^a   Süsal, Caner ^a   Kopp, Brigitte ^b   Opelz, Gerhard ^a   Terness, Peter ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Apoptosis; Bufadienolide; Cardiac glycoside; Cytotoxic action; Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; BUFADIENOLIDE; BUFADIENOLIDE GLYCOSIDE; CASPASE 3 INHIBITOR; CASPASE 8 INHIBITOR; CASPASE 9 INHIBITOR; CASPASE INHIBITOR; CHEMICAL COMPOUND; DNA FRAGMENT; GENTAMICIN; PHOSPHATIDYLSERINE; PROTEIN BCL 2; STEROID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD; CANCER CELL; CANCER THERAPY; CELL ACTIVITY; CELL DEATH; CELL KILLING; CELL NUCLEUS; CHEMICAL MODIFICATION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; DATA ANALYSIS; DRUG ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; HEART CONTRACTION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOBLAST; TIME;

EID: 0242495693     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2003.08.004     Document Type: Article

References (49)

1. Krenn L., Kopp B. Bufadienolides from animal and plant sources. Phytochemistry. 48:1998;1-29.
2. Zhang L.S., Nakaya K., Yoshida T., Kuroiwa Y. Bufalin as a potent inducer of differentiation of human myeloid leukemia cells. Biochem. Biophys. Res. Commun. 178:1991;686-693.
3. Jing Y., Ohizumi H., Kawazoe N., Hashimoto S., Masuda Y., et al. Selective inhibitory effect of bufalin on growth of human tumor cells in vitro: association with the induction of apoptosis in leukemia HL-60 cells. Jpn. J. Cancer Res. 85:1994;645-651.
4. Masuda Y., Kawazoe N., Nakajo S., Yoshida T., Kuroiwa Y., Nakaya K. Bufalin induces apoptosis and influences the expression of apoptosis-related genes in human leukemia cells. Leuk. Res. 19:1995;549-556.
5. Watabe M., Ito K., Masuda Y., Nakajo S., Nakaya K. Activation of AP-1 is required for bufalin-induced apoptosis in human leukemia U937 cells. Oncogene. 16:1998;779-787.
6. Kawazoe N., Watabe M., Masuda Y., Nakajo S., Nakaya K. Tiam1 is involved in the regulation of bufalin-induced apoptosis in human leukemia cells. Oncogene. 8:1999;2413-2421.
7. Shiratsuchi A., Nakanishi Y. Phosphatidylserine-mediated phagocytosis of anticancer drug-treated cells by macrophages. J. Biochem. 126:1999;1101-1106.
8. Kerr J.F.R., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer. 26:1972;239-257.
9. Pierce G.B., Lewellyn A.L., Parchment R.E. Mechanism of programmed cell death in the blastocyst. Proc. Natl. Acad. Sci. 86:1989;3654-3658.
10. Vaux D.L., Cory S., Adams J.M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 335:1988;440-442.
11. Laurent-Crawford A.G., Krust B., Muller S., Riviere Y., Rey-Cuille, et al. The cytopathic effect of HIV is associated with apoptosis. Virology. 185:1991;829-839.
12. Liu X., Zou H., Slaughter C., Wang X. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell. 89:1997;175-184.
13. Sakahira H., Enari M., Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature. 391:1998;96-99.
14. Kluck R.M., Bossy-Wetzel E., Green D.R., Newmeyer D.D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 275:1997;1132-1136.
15. Hockenbery D.M., Oltvai Z.N., Yin X.M., Milliman C.L., Korsmeyer S.J. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell. 75:1993;241-251.
16. Zamzami N., Susin S.A., Marchetti P., Hirsch T., Gomez-Monterrey I., et al. Mitochondrial control of nuclear apoptosis. J. Exp. Med. 183:1996;1533-1544.
17. Terness P., Navolan D., Dufter C., Kopp B., Opelz G. The T-cell suppressive effect of bufadienolides: structural requirements for their immunoregulatory activity. Int. Immunopharmacol. 1:2001;119-134.
18. Huber P., Linde H., Meyer K. Konstitution des Cinobufagins. Helv. Chim. Acta. 43:1960;1955-1967.
19. Linde H., Meyer K. Konstitution des Resibufogenins. Helv. Chim. Acta. 42:1959;807-826.
20. Huber K., Linde H., Meyer K. ψ-Bufarenogin, ein neues Bufadienolid aus Ch'an Su und Umlagerungsprodukt des Arenobufagins sowie Bemerkung zur Konfiguration des Bufarenogins. Helv. Chim. Acta. 50:1967;1994-2008.
21. Huber K., Linde H., Meyer K. Konstitution des Arenobufagins. Helv. Chim. Acta. 43:1960;1950-1955.
22. Armstrong R.C., Aja T., Xiang J., Gaur S., Krebs J.F., et al. Fas-induced activation of the cell death-related protease CPP32 is inhibited by Bcl-2 and by ICE family protease inhibitors. J. Biol. Chem. 271:1996;16850- 16855.
23. Martin S.J., Reutelingsperger C.P.M., McGahon A.J., Rader J.A., van Schie R.C., et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of bcl-2 and abl. J. Exp. Med. 182:1995;1545-1556.
24. + ions. J. Biochem. 126:1999;278-286.
25. Nunez G., Benedict M.A., Hu Y., Inohara N. Caspases: the proteases of apoptotic pathway. Oncogene. 17:1998;3237-3245.
26. Yang J., Liu X., Bhalla K., Kim C.N., Ibrado A.M., et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 275:1997;1129-1132.
27. Shimizu S., Eguchi Y., Kamiike W., Funahashi Y., Mignon A., et al. Bcl-2 prevents apoptotic mitochondrial dysfunction by regulating proton flux. Proc. Natl. Acad. Sci. U. S. A. 95:1998;1455-1459.
28. Shimizu S., Eguchi Y., Kamiike W., Waguri S., Uchiyama Y., et al. Bcl-2 blocks loss of mitochondrial membrane potential while ICE inhibitors act at a different step during inhibition of death induced by respiratory chain inhibitors. Oncogene. 13:1996;21-29.
29. Fulda S., Scaffidi C., Susin S.A., Krammer P.H., Kroemer G., et al. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J. Biol. Chem. 273:1998;33942-33948.
30. Klaus S.J., Sidorenko S.P., Clark E.A. CD45 ligation induces programmed cell death in T and B lymphocytes. J. Immunol. 156:1996;2743-2753.
31. Bernard G., Breittmayer J.P., De Matteis M., Trampont P., Hofman P., et al. Apoptosis of immature thymocytes mediated by E2/CD99. J. Immunol. 158:1997;2543-2550.
32. Stenkvist B. Is digitalis a therapy for breast carcinoma? Oncol. Rep. 6:1999;493-496.
33. Stenkvist B., Bengtsson E., Eriksson O., Holmquist J., Nordin B., et al. Cardiac glycosides and breast cancer. Lancet. 1:1979;563.
34. Stenkvist B., Bengtsson E., Eklund G., Eriksson O., Holmquist J., et al. Evidence of a modifying influence of heart glycosides on the development of breast cancer. Anal. Quant. Cytol. Histol. 2:1980;49-54.
35. Förster W. Struktur-Wirkungsbeziehungen bei Cardenoliden und Bufadienoliden. Baumgarten G., Förster W. Die Herzwirksamen Glykoside. Herkunft, Chemie und Grundlagen ihrer pharmakologischen und klinischen Wirkung. 1963;199-233 VEB Georg Thieme, Leipzig.
36. Goto A., Yamada K., Yagi N., Yoshioka M., Sugimoto T. Physiology and pharmacology of endogenous digitalis-like factors. Pharmacol. Rev. 44:1992;377-399.
37. Greenstein S., Ghias K., Krett N.L., Rosen S.T. Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin. Cancer Res. 8:2002;1681-1694.
38. Guyre PM, Munck A. Glucocorticoids. In: Delves PJ, Roitt IM, editors. Encyclopedia of immunology. New York: Academic Press, Harcourt Brace and Company Publishers; 1998. p. 996-1001.
39. Repke K.R.H., Weiland J., Menke K.H. Chemical models for the nature of endogenous digitalis. J. Enzyme Inhib. 5:1991;25-32.
40. +-ATPase. Sandler M., Smith H.J. Design of enzyme inhibitors as drugs. 1989;435-501 Oxford Univ. Press, Oxford.
41. +-ATPase inhibition in K562 cell differentiation induced by bufalin. J. Cell. Physiol. 160:1994;113-120.
42. Kaplan J.H. Biochemistry of Na,K-ATPase. Annu. Rev. Biochem. 71:2002;511-535.
43. Watabe M., Masuda Y., Nakajo S., Yoshida T., Kuroiwa Y., Nakaya K. The cooperative interaction of two different signaling pathways in response to bufalin induces apoptosis in human leukemia U937 cells. J. Biol. Chem. 271:1996;14067-14073.
44. Watabe M., Kawazoe N., Masuda Y., Nakajo S., Nakaya K. Bcl-2 protein inhibits bufalin-induced apoptosis through inhibition of mitogen-activated protein kinase activation in human leukemia U937 cells. Cancer Res. 57:1997;3097-3100.
45. Kaioumova D., Suesal C., Opelz G. Induction of apoptosis in human lymphocytes by the herbicide 2,4-dichlorophenoxyacetic acid. Hum. Immunol. 62:2001;64-74.
46. Messmer U.K., Reed U.K., Brune B. Bcl-2 protects macrophages from nitric oxide-induced apoptosis. J. Biol. Chem. 271:1996;20192-20197.
47. Budijardjo I., Oliver H., Lutter M., Luo X., Wang X. Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol. 15:1999;269-290.
48. Hashimoto S., Jing Y., Kawazoe N., Masuda Y., Nakajo S., et al. Bufalin reduces the level of topoisomerase II in human leukemia cells and affects the cytotoxicity of anticancer drugs. Leuk. Res. 21:1997;875-883.
49. Kurosawa M., Tani Y., Nishimura S., Numazawa S., Yoshida T. Distinct PKC isoenzymes regulate bufalin-induced differentiation and apoptosis in human monocytic cells. Am. J. Cell Physiol. 280:2001;459-464.